JGC
ACLX

J. Goldman & Co’s Arcellx ACLX Stock Holding History

J. Goldman & Co’s Portfolio ACLX Stock Details ACLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,219
Closed -$2.04M – 646
2025
Q4 		$2.04M Buy
+31,219
New +$2.49M 0.05% 312

Other funds holding ACLX

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

J. Goldman & Co's ACLX Position: Q1 2026 in Review

J. Goldman & Co sold out of Arcellx (ACLX) in Q1 2026, closing a stake of 31,219 shares — an estimated $2.04M sold.

J. Goldman & Co first reported a position in ACLX in Q4 2025 and held it in 1 quarter. The position peaked at $2.04M in Q4 2025. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

  • J. Goldman & Co reported no remaining Arcellx position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 31,219 Arcellx shares in Q1 2026, an estimated $2.04M.
  • J. Goldman & Co first reported a position in Arcellx in Q4 2025 and held it in 1 quarter.
  • J. Goldman & Co's Arcellx position peaked at $2.04M in Q4 2025.
  • 239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.